Business
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Total Revenues of $451.1 Million for the Fourth Quarter of 2021, $1.43 Billion for the Full Year 2021 - - Cabozantinib franchise achieved a significant
About this update from Exelixis, Inc.
[{"type":"text","content":"\n- Total Revenues of $451.1 Million for the Fourth Quarter of 2021, $1.43 Billion for the Full Year 2021 -\n\n- Cabozantinib franchise achieved a significant milestone with $1.08 Billion in U.S. Net Product Revenues for the Full Year 2021, including $302.7 Million for the Fourth Quarter 2021 -\n\n- GAAP Diluted EPS of $0.29 for the Fourth Quarter of 2021, $0.72 for the Full Year 2021 -\n\n- Non-GAAP Diluted EPS of $0.35 for the Fourth Quarter of 2021, $1.01 for the Full Year 2021 -\n\n- Conference Call and Webcast Today at 5:00 PM Eastern Time -\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nExelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.\n\n“The Exelixis team made significant progress across our entire business in the fourth quarter and throughout 2021,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “With strong performance from CABOMETYX® in the fourth quarter, the cabozantinib franchise achieved two significant commercial milestones in 2021 with Exelixis full year U.S. net product revenues exceeding $1 billion and global net product revenues generated by Exelixis and its partners of more than $1.5 billion. These major milestones reflect the importance of our flagship product not only as a treatment for multiple serious cancers, but as the foundation for our company’s growth, enabling the buildout of our clinical pipeline and fueling our ambition to become a global, multiproduct oncology company.”\n\nDr. Morrissey continued: “In late 2021 and early 2022, we achieved multiple key pipeline and discovery milestones, including expanding the phase 1b clinical program for XL092, advancing the phase 1 development of XB002 and XL102, in-licensing and progressing XL114 toward the clinic, and expanding our portfolio through new business development agreements. Collectively, our four clinical compounds and more than 10 discovery programs represent an exciting, diverse portfolio of therapeutic candidates with the potential to improve outcomes for patients with cancer. I’m grateful to the Exelixis team for their continued focus, commitment and hard work as we advance our mission to help cancer patients recove...